DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Alipogene tiparvovec
Alipogene tiparvovec
(AAV1-LPLS447X) Gene Therapy for Lipoprotein Lipase Deficiency
Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
Small Dense Low-Density Lipoprotein: Biomarker Or Potential Drug Target?
Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark
LAI Expert Consensus Statement
The Personalized Medicine Report
2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis
Small Dense Low-Density Lipoprotein: Biomarker Or Potential Drug Target?
2 12/ 35 74Al
Alipogene Tiparvovec (AMT-011, Glybera) for Lipoprotein Lipase Deficiency
The National Institute for Health and Care Excellence
Nutrients 2013, 5, 981-1001; Doi:10.3390/Nu5030981 OPEN ACCESS Nutrients ISSN 2072-6643 Article Hypertriglyceridemia
Lipid Therapeutics Update - Going Above and Beyond Statin Therapy
The Importance of Lipoprotein Lipase Regulationin Atherosclerosis
Alipogene Tiparvovec: a Review of Its Use in Adults with Familial Lipoprotein Lipase Deficiency
2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
Top View
2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
Rare Dyslipidaemias, from Phenotype to Genotype to Management: a European Atherosclerosis Society Task Force Consensus Statement
Glybera, INN-Alipogene Tiparvovec
Decade in Review—Dyslipidaemia: Resurgence of Targets And
Emerging Strategies of Targeting Lipoprotein Lipase for Metabolic and Cardiovascular Diseases
Biosimilar Product Differences Will Affect US Uptake, Amgen Predicts
Literature Update Week 05 (2019) [1] Cardellini M, Rovella V, Scimeca M
Alipogene Tiparvovec: Gene Therapy for Lipoprotein Lipase Deficiency
Glybera, INN-Alipogene Tiparvovec
WHO Prequalification of Medicines
Agenda of PDCO Meeting of 27-29 January 2016
Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark∗
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Suggested Reading List
Regulatory Change in Pharmaceutical Price: Evidence from A
Complex Dyslipidemias: Challenges in Management
FDA Briefing Document Endocrinologic and Metabolic
Management of Hypertriglyceridemia BMJ: First Published As 10.1136/Bmj.M3109 on 12 October 2020
Lipid Modification to Reduce Cardiovascular Risk
'Essays in Regulation of Pharmaceutical Markets'
Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine
Tenofovir Alafenamide
List Item CHMP Summary of Positive Opinion for Glybera
PRAC Draft Agenda of Meeting 28 November
Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark
Non-Interventional Study Protocol
Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving